Selpercatinib Approved for Metastatic MTC

In September, selpercatinib (also known as LOXO) was approved in England (Cancer Drugs Fund) and Scotland (Interim Basis) for use in metastatic RET-mutation medullary thyroid cancer (MTC) as well as other RET-fusion positive thyroid cancers.

Get Ready for Thyroid Cancer Awareness Month!

September is Thyroid Cancer Awareness Month, and we'll be raising awareness of medullary thyroid cancer.  Here's how you can help.....!

Click here for more information